Søren Tulstrup new CEO of Vifor Pharma

Søren Tulstrup joins Vifor Pharma from Shire Pharmaceuticals, where he was Head of Global Franchise with responsibility for Elaprase® Hunter syndrome or mucopolysaccharidosis type II (MPS II)) as well as the development of new MPS medications. Before joining Shire, Søren was President and CEO of Santaris Pharma A/S, a biopharmaceutical company specialising in the development of RNA-targeted (ribonucleic acid) medications for various therapeutic areas. He has a wealth of experience in various roles as a commercial and general manager at companies such as Abbott Laboratories (AbbVie), Sandoz Pharma Ltd. (Novartis) and Merck & Co. Søren has a Master of Science, Economics and Business Administration from Copenhagen Business School.


Dario Eklund appointed as new Head of Global Business Operations, Vifor Pharma

Dario Eklund joins Vifor Pharma from Organogenesis Inc. in Boston, USA, where he was Vice President with responsibility for non-US operations, business development and licensing and the Gintuit business unit. Prior to that, Mr. Eklund was General Manager of Aventis Pharma (now Sanofi) in Switzerland, which he joined after several roles of increasing responsibility, such as Commercial Director, Area Manager Eastern Europe & Israel and Country Manager, at Novartis in Basel. Mr. Eklund holds a master's degree from the Swedish School of Economics and Business Administration in Helsinki, Finland.


Abdul Mullick appointed as new Head of Global Marketing, Vifor Pharma

Abdul Mullick was most recently Vice President and General Manager, endocrinology and cardiology, in the rare diseases division of Sanofi (formerly Genzyme) in Boston, where he led the US and international operations; and prior to this, he was responsible for global marketing for rare genetic diseases. Before moving to Boston, he spent several years with Genzyme in Europe where he led the endocrine and renal business unit in the Asia-Pacific region and the endocrine business unit in Europe. Before joining Genzyme, Mr. Mullick held a number of positions at Novartis, including Senior Global Brand Lead with responsibility for the diabetes franchise. Mr. Mullick has a Ph.D. in molecular biology from The University of Bristol, England.

Both positions report directly to the CEO of Vifor Pharma Søren Tulstrup and are based at the headquarters in Zurich, Switzerland.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.